fashion -WSS

fashion

author：hotspot 2025-09-06 02:16:50 - browse：66

The future looks even brighter for the blockbuster Enhertu, showcased here at ASCO. ADAM FEUERSTEIN/STAT

CHICAGO — The cancer drug Enhertu stalled the growth of tumors by more than a year, significantly longer than standard chemotherapy did in women with the most common form of metastatic breast cancer — a clinical trial result that once again promises to rewrite the rules for the treatment of the disease.

The makers of Enhertu, Daiichi Sankyo and AstraZeneca, said the new data, if cleared by regulators, could shift the way physicians treat hormone receptor-positive, metastatic breast cancer, and create a new standard of care in which patients with breast tumors that express even the faintest amount of HER2 protein can benefit.

“It’s not an overestimation to say that trastuzumab deruxtecan is the most potent drug ever developed for breast cancer,” said Paolo Tarantino, a medical oncologist at the Dana-Farber Cancer Institute, using the scientific name for Enhertu. “It does come with side effects that we’re learning to manage, but with that said, I’ve never seen data like what’s being reported here.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Telehealth startups are trying to fill the menopause care vacuum

WSS

US jobless claims fall again as labor market continues to flash strength

This biotech could one day make human eggs from scratch. But first, they’re trying to rethink IVF

Why are elite athletes different? Take a look at their microbes

Thousands of UK hospital doctors walk out in the latest pay dispute, crippling health services

Do masks work? RCTs can't tell us

WATCH: Why do fingernails fall off when they're damaged?

focus

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Medicare details structure of new drug price negotiation program

Jan. 6 charges against Trump would add to his mounting legal peril as he campaigns for 2024

FDA approval of Sarepta Duchenne genetic therapy gives me hope

The strategy behind pharma's lawsuits over drug pricing reform

Jerome Adams on the need for new antivirals for Covid

FDA panel unanimously endorses Eisai’s Alzheimer’s drug Leqembi

Heart attack and stroke risk calculators need revising

Death of patient in Alzheimer’s trial raises question of possible risks

Medical records are filled with copy

Delta passengers in Vegas fall sick while waiting on flight in triple

Wikipedia

What is the Wagner Group? The 'brutal' Russian military unit in Ukraine

US jobless claims fall again as labor market continues to flash strength

What would happen to your eyes if you looked at the solar eclipse?

Colonoscopy at 40? Study finds a possible benefit

Do masks work? RCTs can't tell us

STAT's guide to the next generation of CAR

entertainment

Wikipedia

focus

entertainment